Related Experiment Videos
Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta
Stefan Weigand1, Hilmar Bischoff, Elke Dittrich-Wengenroth
1BAYER Health Care AG, Pharma Research, D-42096 Wuppertal, Germany. stefan.weigand@roche.com
Bioorganic & Medicinal Chemistry Letters
|August 24, 2005
Summary
Researchers developed new small-molecule agonists targeting human peroxisome proliferator-activated receptor delta (PPARdelta). Compound 33 demonstrated favorable pharmacokinetic properties, indicating potential for further development.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor delta (PPARdelta) is a nuclear receptor involved in metabolic regulation.
- Modulating PPARdelta activity is a therapeutic strategy for various diseases.
Purpose of the Study:
- To synthesize and characterize novel small-molecule agonists of human PPARdelta.
- To evaluate the pharmacological properties of these novel compounds.
Main Methods:
- Solid-phase synthesis was employed to generate a library of PPARdelta agonists.
- Pharmacological evaluation assessed the activity and properties of the synthesized compounds.
Main Results:
- A new series of small-molecule PPARdelta agonists was successfully synthesized.
- Compound 33 exhibited promising pharmacokinetic profiles.
Conclusions:
- The developed compounds represent a new class of potential PPARdelta-targeting therapeutics.
- Compound 33 warrants further investigation due to its favorable pharmacokinetics.